查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
血液學惡性腫瘤檢測市場 - 2017-2027年全球行業規模、佔有率、趨勢、機會和預測，按成分、技術、治療指徵、終端用戶、公司和地區分類
市場調查報告書
商品編碼
1289650

血液學惡性腫瘤檢測市場 - 2017-2027年全球行業規模、佔有率、趨勢、機會和預測，按成分、技術、治療指徵、終端用戶、公司和地區分類

Hematologic Malignancies Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Component, By Technique, By Therapeutic Indication, By End User, By company and By Region
出版日期: | 出版商: TechSci Research | 英文 114 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

在2023-2027年的預測期內，全球血液惡性腫瘤檢測市場預計將出現令人矚目的成長。主要因素，包括血癌發生率的增加和技術的廣泛發展，正在推動市場的成長。血液學惡性腫瘤是影響血液、骨髓和淋巴結的癌症。白血病、淋巴瘤和骨髓瘤是血癌的常見類型。血液學惡性腫瘤檢測是一種有助於診斷血癌的醫學檢測方法。支持市場成長的其他因素有：研發活動的增加，政府資金的增加，對個性化醫療的重視，患者和醫療專業人士意識的增加，老齡化人口的增加，無機成長戰略的增加，產品推出的數量增加，以及新興子市場的巨大潛力。

血液相關疾病的發生率不斷增加

血液相關疾病，如白血病、淋巴瘤和骨髓瘤的發病率不斷增加，正在推動全球市場的成長。根據美國癌症協會的數據，在美國，大約每3分鐘就有一個人被診斷出患有白血病、淋巴瘤和骨髓瘤。由於患有血液病的病人數量增加，對血癌的早期檢測和治療的需求激增，從而促進了市場的成長。血癌是全球第五大最常見的惡性腫瘤，也是癌症死亡的第二個主要原因。例如，全球每年有30多萬人被診斷為白血病，40多萬人被診斷為淋巴瘤。

技術進步和研發活動的增加

醫療保健領域新技術的發展正在推動市場的成長。擴大採用新的創新技術，如數位PCR、下一代測序、細胞遺傳學和其他，正在加強市場的成長。這些發展有助於最大限度地減少治療的成本和時間，提高人類生活品質。此外，研發活動的增加正在推動市場的成長。

擴大採用無機成長戰略

越來越多的無機成長戰略，如合併、收購、合作、夥伴關係，以及市場參與者推出越來越多的產品，正在推動市場的成長。例如，2021年，Natera公司和Personalis公司在個性化腫瘤學方面建立了夥伴關係，將Personalis公司的NeXT腫瘤分析和診斷產品與Natera公司的個性化ctDNA平台Signatera結合起來，用於治療監測和分子殘餘疾病評估。同樣，在2018年，雅培推出了融合了血液學系統的h系列，並在此後給臨床實驗室帶來了眾多變化。

可用的定製服務

利用給定的市場數據，TechSci Research根據公司的具體需求提供定製服務。該報告有以下定製選項：

公司資訊

  • 對其他市場參與者（最多五個）的詳細分析和簡介。

目錄

第一章：產品概述

第二章：研究方法

第三章：執行摘要

第四章：COVID-19對全球血液學惡性腫瘤檢測市場的影響

第五章：客戶的聲音

第六章：臨床試驗分析

第七章：全球血液學惡性腫瘤檢測市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率與預測
    • 按組件（試劑盒和服務）分類
    • 按技術分類（下一代測序（NGS）、聚合酶鍊式反應（PCR）、螢光原位雜交（FISH）、免疫組織化學（IHC）、其他）
    • 按治療適應症（白血病、淋巴瘤、多發性骨髓瘤、骨髓增生性腫瘤、其他）
    • 按終端用戶（醫院和診所、診斷實驗室、學術和研究機構、其他）分類
    • 按公司分類（2021年）
    • 按地區分類
  • 市場地圖

第八章：北美血液學惡性腫瘤檢測市場展望

  • 市場規模和預測
    • 按價值分類
  • 市場佔有率與預測
    • 按組件（試劑盒和服務）分類
    • 按技術分類（下一代測序（NGS）、聚合酶鍊式反應（PCR）、螢光原位雜交（FISH）、免疫組織化學（IHC）、其他）
    • 按治療適應症（白血病、淋巴瘤、多發性骨髓瘤、骨髓增生性腫瘤、其他）
    • 按終端用戶（醫院和診所、診斷實驗室、學術和研究機構、其他）分類
    • 按國家分類
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第九章：歐洲血液學惡性腫瘤檢測市場展望

  • 市場規模和預測
    • 按價值計算
  • 市場佔有率與預測
    • 按組件（試劑盒和服務）分類
    • 按技術分類（下一代測序（NGS）、聚合酶鏈反應（PCR）、螢光原位雜交（FISH）、免疫組化（IHC）、其他）
    • 按治療適應症（白血病、淋巴瘤、多發性骨髓瘤、骨髓增生性腫瘤、其他）
    • 按終端用戶（醫院和診所、診斷實驗室、學術和研究機構、其他）分類
    • 按國家分類
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第十章：亞太地區血液學惡性腫瘤檢測市場展望

  • 市場規模和預測
    • 按價值計算
  • 市場佔有率與預測
    • 按組件（試劑盒和服務）分類
    • 按技術分類（下一代測序（NGS）、聚合酶鍊式反應（PCR）、螢光原位雜交（FISH）、免疫組織化學（IHC）、其他）
    • 按治療適應症（白血病、淋巴瘤、多發性骨髓瘤、骨髓增生性腫瘤、其他）
    • 按終端用戶（醫院和診所、診斷實驗室、學術和研究機構、其他）分類
    • 按國家分類
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳大利亞

第11章：南美血液學惡性腫瘤檢測市場展望

  • 市場規模和預測
    • 按價值計算
  • 市場佔有率與預測
    • 按組件（試劑盒和服務）分類
    • 按技術分類（下一代測序（NGS）、聚合酶鏈反應（PCR）、螢光原位雜交（FISH）、免疫組化（IHC）、其他）
    • 按治療適應症（白血病、淋巴瘤、多發性骨髓瘤、骨髓增生性腫瘤、其他）
    • 按終端用戶（醫院和診所、診斷實驗室、學術和研究機構、其他）分類
    • 按國家分類
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第十二章：中東和非洲血液學惡性腫瘤檢測市場展望

  • 市場規模和預測
    • 按價值計算
  • 市場佔有率與預測
    • 按組件（試劑盒和服務）分類
    • 按技術分類（下一代測序（NGS）、聚合酶鏈反應（PCR）、螢光原位雜交（FISH）、免疫組化（IHC）、其他）
    • 按治療適應症（白血病、淋巴瘤、多發性骨髓瘤、骨髓增生性腫瘤、其他）
    • 按終端用戶（醫院和診所、診斷實驗室、學術和研究機構、其他）分類
    • 按國家分類
  • MEA: 國家分析
    • 南非血液學惡性腫瘤檢測
    • 沙烏地阿拉伯血液學惡性腫瘤檢測
    • 阿拉伯聯合大公國血液學惡性腫瘤檢測
    • 土耳其血液學惡性腫瘤測試
    • 埃及血液學惡性腫瘤檢測

第十三章：市場動態

  • 驅動力
  • 挑戰

第十四章：市場趨勢與發展

第十五章：競爭格局

  • Abbott Laboratories, Inc.
  • Asuragen Inc.
  • Bio-Rad Laboratories, Inc.
  • Adaptive Biotechnologies Corporation
  • F.Hoffmann-La-Roche AG
  • Illumina, Inc.
  • ICON plc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Invivoscribe, Inc.

第16章：戰略建議

簡介目錄
Product Code: 13004

The global hematologic malignancies testing market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors, including growing occurrences of blood cancer and extensive development in technology, are fueling the growth of the market. Hematologic malignancies are cancers that affect the blood, bone marrow, and lymph nodes. Leukemia, lymphoma, and myeloma are the common types of blood cancer. Hematologic malignancies testing is a medical testing method that helps to diagnose blood cancer. The other factors supporting the market's growth are a rise in R&D activities, increasing favorable government funding, rising emphasis on personalized medicine, increasing awareness among patients and healthcare professionals, rise in aging population base, growing adoption of inorganic growth strategies, an increasing number of product launches, and immense potential for emerging submarkets.

Increasing Occurrence of Blood-Related Disorders

The growing incidences of blood-related disorders, such as leukemia, lymphoma, and myeloma, are bolstering the growth of the market globally. According to the American Cancer Society, in the United States, around every 3 minutes, a person is diagnosed with leukemia, lymphoma, and myeloma. Owing to the rise in the number of patients who have hematologic cancer, the surge in the need for early detection and treatment of blood cancers is augmenting the growth of the market. Blood cancers are the fifth most common malignancy across the world and the second primary reason for cancer death. For instance, more than 300,000 people are diagnosed yearly with leukemia and 400,000 with lymphoma across the globe.

Technological Advancements and Rise in R&D Activities

The evolution of new technologies in the healthcare sector is surging the growth of the market. The increasing adoption of new innovative technologies, such as digital PCR, next-generation sequencing, cytogenetics, and others, is strengthening the growth of the market. The developments are helping to minimize the cost and time of treatment and improve the quality of human life. Moreover, the rise in R&D activities is propelling the growth of the market.

Increasing Adoption of Inorganic Growth Strategies

Growing inorganic growth strategies such as mergers, acquisitions, collaborations, partnerships, and an increasing number of product launches by market players are bolstering the growth of the market. For instance, in 2021, Natera, Inc., and Personalis, Inc. partnered in personalized oncology by coupling Personalis' NeXT tumor profiling and diagnostic products with Natera's personalized ctDNA platform Signatera for treatment monitoring and molecular residual disease assessment. Similarly, in 2018, Abbott launched an h-series incorporating a hematology system and has brought numerous changes in the clinical laboratories since then.

Market Segmentation

The global hematologic malignancies testing market is segmented into component, technique, therapeutic indication, end user, and company. Based on components, the market is divided into kits and services. Based on kits, the market is further divided into gene panels, molecular clonality testing, translocation testing, mutation testing, and others. Based on technique, the market is divided into next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in-situ hybridization (FISH), immunohistochemistry (IHC), and others. Based on therapeutic indication, the market is divided into leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasms, and others. Based on end-user, the market is divided into hospitals & clinics, diagnostic laboratories, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising incidences of blood cancers in the country.

Market Players

Abbott Laboratories, Inc., Asuragen Inc., Bio-Rad Laboratories, Inc., Adaptive Biotechnologies Corporation, F.Hoffmann-La-Roche AG, Illumina, Inc., ICON plc., Invitae Corporation, Laboratory Corporation of America Holdings, and Invivoscribe, Inc. are some of the leading companies operating in the market.

Report Scope

In this report, global hematologic malignancies testing market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hematologic Malignancies Testing Market, By Component:

  • Kits
    • Gene Panels
    • Molecular Clonality Testing
    • Translocation Testing
    • Mutation Testing
    • Others
  • Services

Hematologic Malignancies Testing Market, By Component:

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Fluorescence In-Situ Hybridization (FISH)
  • Immunohistochemistry (IHC)
  • Others

Hematologic Malignancies Testing Market, By Therapeutic Indication:

  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Myeloproliferative Neoplasms
  • Others

Hematologic Malignancies Testing Market, By End User:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Academic & Research Institutions
  • Others

Hematologic Malignancies Testing Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Turkey

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Hematologic Malignancies Testing Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Hematologic Malignancies Testing Market

5. Voice of Customer

6. Clinical Trial Analysis

7. Global Hematologic Malignancies Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Component (Kits v/s Services)
      • 7.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
    • 7.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 7.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
    • 7.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 7.2.5. By Company (2021)
    • 7.2.6. By Region
  • 7.3. Market Map

8. North America Hematologic Malignancies Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Component (Kits v/s Services)
      • 8.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
    • 8.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 8.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
    • 8.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 8.2.5. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Hematologic Malignancies Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Component
        • 8.3.1.2.2. By Technique
        • 8.3.1.2.3. By Therapeutic Indication
        • 8.3.1.2.4. By End User
    • 8.3.2. Canada Hematologic Malignancies Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Component
        • 8.3.2.2.2. By Technique
        • 8.3.2.2.3. By Therapeutic Indication
        • 8.3.2.2.4. By End User
    • 8.3.3. Mexico Hematologic Malignancies Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Component
        • 8.3.3.2.2. By Technique
        • 8.3.3.2.3. By Therapeutic Indication
        • 8.3.3.2.4. By End User

9. Europe Hematologic Malignancies Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Component (Kits v/s Services)
      • 9.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
    • 9.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 9.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
    • 9.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 9.2.5. By Country
  • 9.3. Europe: Country Analysis
    • 9.3.1. France Hematologic Malignancies Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Component
        • 9.3.1.2.2. By Technique
        • 9.3.1.2.3. By Therapeutic Indication
        • 9.3.1.2.4. By End User
    • 9.3.2. Germany Hematologic Malignancies Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Component
        • 9.3.2.2.2. By Technique
        • 9.3.2.2.3. By Therapeutic Indication
        • 9.3.2.2.4. By End User
    • 9.3.3. United Kingdom Hematologic Malignancies Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Component
        • 9.3.3.2.2. By Technique
        • 9.3.3.2.3. By Therapeutic Indication
        • 9.3.3.2.4. By End User
    • 9.3.4. Italy Hematologic Malignancies Testing Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Component
        • 9.3.4.2.2. By Technique
        • 9.3.4.2.3. By Therapeutic Indication
        • 9.3.4.2.4. By End User
    • 9.3.5. Spain Hematologic Malignancies Testing Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Component
        • 9.3.5.2.2. By Technique
        • 9.3.5.2.3. By Therapeutic Indication
        • 9.3.5.2.4. By End User

10. Asia-Pacific Hematologic Malignancies Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Component (Kits v/s Services)
      • 10.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
    • 10.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 10.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
    • 10.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 10.2.5. By Country
  • 10.3. Asia-Pacific: Country Analysis
    • 10.3.1. China Hematologic Malignancies Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Component
        • 10.3.1.2.2. By Technique
        • 10.3.1.2.3. By Therapeutic Indication
        • 10.3.1.2.4. By End User
    • 10.3.2. India Hematologic Malignancies Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Component
        • 10.3.2.2.2. By Technique
        • 10.3.2.2.3. By Therapeutic Indication
        • 10.3.2.2.4. By End User
    • 10.3.3. Japan Hematologic Malignancies Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Component
        • 10.3.3.2.2. By Technique
        • 10.3.3.2.3. By Therapeutic Indication
        • 10.3.3.2.4. By End User
    • 10.3.4. South Korea Hematologic Malignancies Testing Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Component
        • 10.3.4.2.2. By Technique
        • 10.3.4.2.3. By Therapeutic Indication
        • 10.3.4.2.4. By End User
    • 10.3.5. Australia Hematologic Malignancies Testing Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Component
        • 10.3.5.2.2. By Technique
        • 10.3.5.2.3. By Therapeutic Indication
        • 10.3.5.2.4. By End User

11. South America Hematologic Malignancies Testing Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Component (Kits v/s Services)
      • 11.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
    • 11.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 11.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
    • 11.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 11.2.5. By Country
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Hematologic Malignancies Testing Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Component
        • 11.3.1.2.2. By Technique
        • 11.3.1.2.3. By Therapeutic Indication
        • 11.3.1.2.4. By End User
    • 11.3.2. Argentina Hematologic Malignancies Testing Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Component
        • 11.3.2.2.2. By Technique
        • 11.3.2.2.3. By Therapeutic Indication
        • 11.3.2.2.4. By End User
    • 11.3.3. Colombia Hematologic Malignancies Testing Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Component
        • 11.3.3.2.2. By Technique
        • 11.3.3.2.3. By Therapeutic Indication
        • 11.3.3.2.4. By End User

12. Middle East and Africa Hematologic Malignancies Testing Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Component (Kits v/s Services)
      • 12.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
    • 12.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 12.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
    • 12.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 12.2.5. By Country
  • 12.3. MEA: Country Analysis
    • 12.3.1. South Africa Hematologic Malignancies Testing Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Component
        • 12.3.1.2.2. By Technique
        • 12.3.1.2.3. By Therapeutic Indication
        • 12.3.1.2.4. By End User
    • 12.3.2. Saudi Arabia Hematologic Malignancies Testing Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Component
        • 12.3.2.2.2. By Technique
        • 12.3.2.2.3. By Therapeutic Indication
        • 12.3.2.2.4. By End User
    • 12.3.3. UAE Hematologic Malignancies Testing Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Component
        • 12.3.3.2.2. By Technique
        • 12.3.3.2.3. By Therapeutic Indication
        • 12.3.3.2.4. By End User
    • 12.3.4. Turkey Hematologic Malignancies Testing Market Outlook
      • 12.3.4.1. Market Size & Forecast
        • 12.3.4.1.1. By Value
      • 12.3.4.2. Market Share & Forecast
        • 12.3.4.2.1. By Component
        • 12.3.4.2.2. By Technique
        • 12.3.4.2.3. By Therapeutic Indication
        • 12.3.4.2.4. By End User
    • 12.3.5. Egypt Hematologic Malignancies Testing Market Outlook
      • 12.3.5.1. Market Size & Forecast
        • 12.3.5.1.1. By Value
      • 12.3.5.2. Market Share & Forecast
        • 12.3.5.2.1. By Component
        • 12.3.5.2.2. By Technique
        • 12.3.5.2.3. By Therapeutic Indication
        • 12.3.5.2.4. By End User

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

15. Competitive Landscape

  • 15.1. Abbott Laboratories, Inc.
  • 15.2. Asuragen Inc.
  • 15.3. Bio-Rad Laboratories, Inc.
  • 15.4. Adaptive Biotechnologies Corporation
  • 15.5. F.Hoffmann-La-Roche AG
  • 15.6. Illumina, Inc.
  • 15.7. ICON plc.
  • 15.8. Invitae Corporation
  • 15.9. Laboratory Corporation of America Holdings
  • 15.10. Invivoscribe, Inc.

16. Strategic Recommendations